Economic evaluation of the impact of nicorandil in angina (IONA) trial.

about

Utility of ranolazine in chronic stable angina patients.Current and Future Challenges for Collaborative Computational Technologies for the Life Sciences

P2860

Q37004023-873FE851-9679-4038-AE11-9AD49296DA76 Q56399692-EDA948A7-21F8-41BF-983F-F516EBCD15F8

P2860

Economic evaluation of the impact of nicorandil in angina (IONA) trial.

Item

http://www.wikidata.org/entity/Q35771735

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Economic evaluation of the impact of nicorandil in angina (IONA) trial.

@ast

Economic evaluation of the impact of nicorandil in angina (IONA) trial.

@en

type

Item

label

Economic evaluation of the impact of nicorandil in angina (IONA) trial.

@ast

Economic evaluation of the impact of nicorandil in angina (IONA) trial.

@en

prefLabel

Economic evaluation of the impact of nicorandil in angina (IONA) trial.

@ast

Economic evaluation of the impact of nicorandil in angina (IONA) trial.

@en

P1476

Economic evaluation of the impact of nicorandil in angina (IONA) trial

@en

P2093

A D McMahon

http://www.w3.org/2001/XMLSchema#string

A Walker

http://www.w3.org/2001/XMLSchema#string

H Dargie

http://www.w3.org/2001/XMLSchema#string

I Ford

http://www.w3.org/2001/XMLSchema#string

K Fox

http://www.w3.org/2001/XMLSchema#string

N J K Henderson

http://www.w3.org/2001/XMLSchema#string

S Hillis

http://www.w3.org/2001/XMLSchema#string

W Berger

http://www.w3.org/2001/XMLSchema#string

P2860

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management

Incidence, clinical characteristics, and short-term prognosis of angina pectoris

Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.

Methodological limitations of cost-effectiveness analysis in health care: implications for decision making and service provision.

Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.

Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.

A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists.

The economic burden of coronary heart disease in the UK.

P304

619-624

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/HRT.2003.026385

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

John McMurray

Simon Stewart

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7166511

http://www.w3.org/2001/XMLSchema#string

P698

16614274

http://www.w3.org/2001/XMLSchema#string

P932

1860935

http://www.w3.org/2001/XMLSchema#string

Economic evaluation of the impact of nicorandil in angina (IONA) trial.

about

P2860

P2860

Economic evaluation of the impact of nicorandil in angina (IONA) trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P932